PHAT PHATHOM PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, PHATHOM PHARMACEUTICALS INC reported revenue of $74.3M (up 88.0% from a year earlier), net income of −$17.6M and diluted EPS of −$0.21; over the last four quarters revenue was $240M and net income $122M; for the fiscal year ended December 2025 revenue was $175M, up 216.9% on the year before.

PHAT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $175M, gross profit $153M, operating income −$160M, net income −$221K (margin -0.1%), EPS −$3.03
• Fiscal year ended Dec 2024: revenue $55.3M, gross profit $47.3M, operating income −$277M, net income −$334K (margin -0.6%), EPS −$5.29
• Fiscal year ended Dec 2023: revenue $682K, gross profit $515K, operating income −$167M, net income −$202K (margin -29.6%), EPS −$3.93
• Fiscal year ended Dec 2022: revenue $0, gross profit $0, operating income −$172M, net income −$198M (margin n/a), EPS −$5.05
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$135M, net income −$144M (margin n/a), EPS −$3.89

PHAT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $74.3M (up 88.0% year over year), net income −$17.6M, EPS −$0.21
• Quarter ended Mar 31, 2026: revenue $58.3M (up 104.4% year over year), net income −$30.4M, EPS −$0.37
• Quarter ended Dec 31, 2025 (from the annual report): revenue $57.6M (up 94.1% year over year), net income $200M, EPS −$0.26
• Quarter ended Sep 30, 2025: revenue $49.5M (up 202.7% year over year), net income −$30.0M, EPS −$0.41
• Quarter ended Jun 30, 2025: revenue $39.5M (up 439.4% year over year), net income −$75.8M, EPS −$1.05
• Quarter ended Mar 31, 2025: revenue $28.5M (up 1391.6% year over year), net income −$94.3M, EPS −$1.31
• Quarter ended Dec 31, 2024 (from the annual report): revenue $29.7M (up 4249.6% year over year), net income $260M, EPS −$0.99
• Quarter ended Sep 30, 2024: revenue $16.4M, net income −$85.6M, EPS −$1.32
• Quarter ended Jun 30, 2024: revenue $7.32M, net income −$91.4M, EPS −$1.56
• Quarter ended Mar 31, 2024: revenue $1.91M, net income −$82.9M, EPS −$1.42
• Quarter ended Dec 31, 2023 (from the annual report): revenue $682K, net income $122M, EPS −$1.44
• Quarter ended Sep 30, 2023: revenue $0, net income −$43.2M, EPS −$0.76
• Quarter ended Jun 30, 2023: revenue $0, net income −$41.0M, EPS −$0.84
• Quarter ended Mar 31, 2023: revenue $0, net income −$37.8M, EPS −$0.89
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$55.0M, EPS −$1.33
• Quarter ended Sep 30, 2022: revenue n/a, net income −$51.1M, EPS −$1.32
• Quarter ended Jun 30, 2022: revenue n/a, net income −$50.9M, EPS −$1.33
• Quarter ended Mar 31, 2022: revenue n/a, net income −$40.7M, EPS −$1.07
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$35.8M, EPS −$0.95
• Quarter ended Sep 30, 2021: revenue n/a, net income −$36.7M, EPS −$0.98

PHAT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$167M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$267M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$138M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$147M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$148M, share buybacks n/a

PHAT balance sheet

• Jun 30, 2026: cash $182M, total assets $327M, total liabilities $671M, shareholders' equity −$344M, long-term debt $165M
• Mar 31, 2026: cash $181M, total assets $305M, total liabilities $642M, shareholders' equity −$337M, long-term debt $164M
• Dec 31, 2025: cash $130M, total assets $259M, total liabilities $697M, shareholders' equity −$438M, long-term debt $209M
• Sep 30, 2025: cash $135M, total assets $240M, total liabilities $663M, shareholders' equity −$423M, long-term debt $207M
• Jun 30, 2025: cash $150M, total assets $250M, total liabilities $656M, shareholders' equity −$406M, long-term debt $205M
• Mar 31, 2025: cash $212M, total assets $294M, total liabilities $633M, shareholders' equity −$338M, long-term debt $203M
• Dec 31, 2024: cash $297M, total assets $378M, total liabilities $632M, shareholders' equity −$254M, long-term debt $201M
• Sep 30, 2024: cash $335M, total assets $387M, total liabilities $574M, shareholders' equity −$187M, long-term debt $176M

What is PHAT's revenue?

PHATHOM PHARMACEUTICALS INC reported $240M of revenue over its last four quarters, through June 30, 2026.

Is PHAT profitable?

Yes. PHATHOM PHARMACEUTICALS INC earned $122M over the last four quarters.

What is PHAT's EPS?

Diluted earnings per share over the last four quarters were −$1.25; −$0.21 in the latest quarter.

PHAT ownership and insider trades · All stocks